Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy InMed Pharmaceuticals stock

Learn how to easily invest in InMed Pharmaceuticals stock.

InMed Pharmaceuticals Inc is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars. InMed Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in InMed Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

InMed Pharmaceuticals stock price (NASDAQ: INM)

Use our graph to track the performance of INM stocks over time.

InMed Pharmaceuticals shares at a glance

Information last updated 2022-01-18.
Latest market close$1.23
52-week range$1.20 - $6.42
50-day moving average $1.48
200-day moving average $2.28
Wall St. target price$6.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.37

Buy InMed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy InMed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InMed Pharmaceuticals price performance over time

Historical closes compared with the close of $1.23 from 2022-01-21

1 week (2022-01-14) -0.81%
1 month (2021-12-23) -18.00%
3 months (2021-10-22) -24.07%
6 months (2021-07-23) -50.80%
1 year (2021-01-22) -69.63%
2 years (2020-01-19) N/A
3 years (2019-01-19) N/A
5 years (2017-01-19) N/A

InMed Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -59.55%
Return on equity TTM -119.13%
Profit margin 0%
Book value $1.47
Market capitalisation $17.5 million

TTM: trailing 12 months

InMed Pharmaceuticals share dividends

We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Have InMed Pharmaceuticals's shares ever split?

InMed Pharmaceuticals's shares were split on a 1:33 basis on 5 July 2020. So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 3200% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.

InMed Pharmaceuticals share price volatility

Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $1.2 up to $6.42. A popular way to gauge a stock's volatility is its "beta".

INM.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 1.4075. This would suggest that InMed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.

InMed Pharmaceuticals overview

InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc.

Frequently asked questions

What percentage of InMed Pharmaceuticals is owned by insiders or institutions?
Currently 0.809% of InMed Pharmaceuticals shares are held by insiders and 7.597% by institutions.
How many people work for InMed Pharmaceuticals?
Latest data suggests 12 work at InMed Pharmaceuticals.
When does the fiscal year end for InMed Pharmaceuticals?
InMed Pharmaceuticals's fiscal year ends in June.
Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals's address is: 815 West Hastings Street, Vancouver, BC, Canada, V6C 1B4
What is InMed Pharmaceuticals's ISIN number?
InMed Pharmaceuticals's international securities identification number is: CA4576375022

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site